Migren baş ağrısında tanı ve tedavi yaklaşımları

Baş ağrısı, genel hasta poliklinikleri ve nöroloji polikliniklerine başvuran hastaların en yoğun şikayetidir. Tanıda, iyi bir öykü alma, nörolojik muayene ve gerekirse görüntüleme yöntemleri kullanılarak, baş ağrısının primer mi yoksa sekonder mi olduğunun saptanması temel esastır. Baş ağrılarının % 90’ı primer tiptir ve bunun çoğunda gerilim tipi baş ağrısı mevcuttur. Ağrı şiddeti, hayat kalitesine etkisi, kişisel ve ülke ekonomisine etkisine bakıldığında, migren, bilinmesi gereken en önemli konudur ki, dünyada yaklaşık 700 milyon migren hastası vardır. Erken ve doğru tanının, iyi bir tedavinin önemi buradan da anlaşılmaktadır. Migren tedavisi ilaç dışı önleyici yöntem ve ilaçlarla atak tedavisini içermektedir. Bu makalede, migren tanı ve tedavisi ile ilgili geçerli bilgilerin derlenmesi amaçlanmıştır.

Migraine headache: Diagnostic and management approaches

Headache is the most common complaint of the patients, who applied to general or neurology outpatient clinics. The essential of the diagnosis based on a detailed anamnesis, neurological examination and appropriate imaging studies. The determination of headache subtype as primary or secondary headache is important. More than 90% of headaches are primary type and most of them are tension headache. While considering headache intensity and its impact on life quality and individual or national economy; migraine can be accepted as one of the most important problems that affected approximately 700 million of world population. The importance of correct and early diagnosis and appropriate management can be understood from this point of view. Management of migraine includes non-pharmacological preventive methods and treatment of acute attacks by drugs. In this study it was aimed to review actual knowledge related to diagnosis and management of migraine headache.

PDF

___

1. Diamond S. A fresh look at migraine therapy. Postgraduate Medicine 2001;109:49-54.
2. Rasmussen BK. Epidemiology of headache. Cephalalgia 2001;21:774-7.
3. World Health Organization. Mental Health: New Understanding, WHO: New Hope Geneva, 2001.
4. Lipton RB, Scher AI, Steiner TJ, et al. Patterns of health care utilization for migraine in England and in the United States. Neurology 2003; 60:441-8.
5. Stewart WF, Schecter A, Rasmussen BK. Migraine prevalence: A review of population based studies. Neurology 1994;44:17-23.
6. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. Cephalalgia 2004;24(Suppl 1):14 -160.
7. Ropper AH, Brown RH. Çeviri: Emre M, Şahin G. Adams and Victor’s Principles of Neurology. 8. Baskı, Ankara, Güneş Kitabevi, 2006, 144-167.
8. Pringsheim T, Edmeads J. Effective treatment of migraine. Postgraduate Med 2004; 115: 28-30.
9. Candelise L, Hughes R, Liberati A, Uitdehaag BMJ, Warlow C. MacGregor A. Çeviri: Siva A. Kanıta Dayalı Nöroloji: Nörolojik Bozuklukların Tedavisi. İstanbul, Sigma Publishing, 2007, 29-39.
10. Silberstein SD. Migraine pathophysiology and its clinical implications. Cephalalgia 2004;24:2-7.
11. Lipchik GL, Jeanette RC. Psychiatric and psychological factors in headache. In: Loder E, Marcus D, eds. Migraine in Women. Hamilton, Ontario: BC Decker Inc, 2004:152-154.
12. Detsky ME, McDonald DR, Baerlocher MO, et al. Does this patient with headache have a migraine or need neuroimaging? JAMA 2006;296:1274-83.
13. Bradley WG, Daroff RB, Fenichel GM, Jankovic J. Çeviri: Tan E, Özdamar SE, Çevik IÜ. Neurogy in Clinical Practice. 5. Baskı, İstanbul, Veri Medikal Yayıncılık, 2008, 263-269.
14. US Headache Consortium. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of a acute attacks. Headache Consortium Guidelines. Asp 2000: Accessed 10 September 2008
15. Ross-Lee LM, Eadie MJ, Hazelwood V, et al. Aspirin pharmacokinetics in migraine. The effect of metoclopramide. Eur J Clin Pharmacol 1983;24:777-85.
16. Johnson RT, Griffin JW, McArthur JC. Troost BT. Çeviri: Bakar M. Current Therapy in Neurologic Diseases, Ankara, Güneş Tıp Kitabevleri, 2007, 67-70.
17. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia 1998;18: 532-8.
18. Dodick D, Lipton RB, Martin V. et al. Triptan Cardiovascular Safety Expert Panel. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 2004; 44:414-25.
19. Tfelt-Hansen P, Saxena PR, Dahlöf C, et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain 2000;123:9-18.
20. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-62.
21. Linde K, Rossnagel K. Propranolol for migraine. Cochrane Database Syst. Review. 2004;2:CD003225
22. Cronicle E, Mulleners W. Anticonvulsant drugs migraine prophylaxis. Cochrane Database Syst. Rev. 2004;3:CD003226
23. Bussone G, Usai S, D’Amico D. Topiramate in migraine prophylaxis: data from a pooled analysis and open-label extension study. Neurol Sci 2006;27:159-63.